Corporate

  • Oct. 2, 2013 biOasis Engages Liolios Group to Lead New Investor Relations Program

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. (TSX.V: BTI, OTCBB: BIOAF), a pioneer in the delivery of therapeutics across the blood-brand barrier, has engaged Liolios Group to lead a new investor relations and financial communications campaign. “Over the course of the last 12 months, leading independent researchers have demonstrated how our Transcend™ technology is able… Read more »

  • Aug. 8, 2013 biOasis Technologies Inc. Announces Notice of Allowance for Key Lysosomal Storage Disease Patent From the US Patent and Trademark Office

    Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application titled “Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes,” US Patent Application Number 12/729,792. The Notice of Allowance is… Read more »

  • Dec. 14, 2012 biOasis Technologies Year in Review 2012

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) today is pleased to provide a 2012 year in review. biOasis has come a long way in 2012. The company has enjoyed a steady, measured progression towards its goals in the execution of its science and business objectives. Through 2012 the company developed a powerful network of highly… Read more »

  • Dec. 3, 2012 biOasis Enters Into a Research Collaboration Agreement with UCB

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into a research collaboration agreement with Brussels, Belgium-based UCB (Euronext Brussels: UCB), to evaluate biOasis’s Transcend technology in the area of the delivery of therapeutic compounds to the brain. In connection with this agreement, biOasis will conduct certain experiments to provide UCB… Read more »

  • Nov. 14, 2012 biOasis Enters Into a Research & Evaluation Agreement with MedImmune

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into a research and evaluation agreement with MedImmune (MedImmune), the global biologics arm of AstraZeneca. Under the terms of this collaboration, biOasis will conduct certain experiments at MedImmune’s expense with the objective of demonstrating that biOasis’s Transcend technology can deliver to the… Read more »

  • Sep. 27, 2012 Experienced Life Science Executive Joins biOasis Board of Directors

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (BTI) is pleased to announce that Mr. Gregory Gubitz has joined the Board of Directors of the Company. Mr. Gubitz is a seasoned life science executive and lawyer, with significant transaction and investment experience. Mr. Gubitz was most recently Senior Vice President, Corporate Development and General Counsel of Biovail… Read more »

  • Jun. 18, 2012 biOasis Enters Research & Evaluation Agreement with Abbott

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into an agreement with Abbott, to evaluate biOasis’s Transcend technology. As consideration for entering into this agreement, undertaking certain activities, and funding a number of experiments, Abbott has been granted certain options to obtain a license to biOasis’ Transcend technology under mutually… Read more »

  • Feb. 16, 2012 biOasis named to TSX Venture 50®

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announces it has been named one of the 2012 TSX Venture 50® companies. The TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada’s junior stock exchange. “We are very proud to be… Read more »

  • Jan. 17, 2012 biOasis Enters Investor Relations Agreement with Brisco Capital Partners Corp.

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) is pleased to announce that it has Brisco Capital Partners Corp. (“Brisco”) to provide investor relations, subject to regulatory approval. Brisco will initiate and maintain contact with the financial community, shareholders, investors and other stakeholders for the purpose of increasing awareness of the Company and… Read more »

  • Nov. 24, 2011 biOasis Enters Research, Evaluation and Option Agreement with Shire Human Genetic Therapies, Inc.

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announced today that it has entered into a research, evaluation and option agreement with Shire Human Genetic Therapies, Inc. (Shire) to evaluate biOasis’s Transcend technology in the area of lysosomal storage disorders (LSDs). In connection with this agreement, biOasis and Shire are undertaking certain experiments at their own… Read more »